Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 13/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | ATF4 | P18848 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2987366 | 0.93 | MCHR1 (0.54) | MCHR1CYP1A2CYP3A4CYP2C19SMN1; SMN2 | |
| SCHEMBL5162540 | 0.93 | MCHR1 (0.46) | MCHR1KCNH2POLBSIGMAR1 | |
| SCHEMBL2972810 | 0.92 | ATF4 (0.55) | MCHR1CYP1A2CYP3A4CYP2C19SMN1; SMN2 | |
| SCHEMBL2987754 | 0.91 | POLB (0.50) | CYP1A2CYP3A4CYP2C19SMN1; SMN2POLB | |
| SCHEMBL2978691 | 0.90 | MCHR1 (0.51) | MCHR1CYP1A2CYP3A4CYP2C19SMN1; SMN2 | |
| SCHEMBL2983707 | 0.89 | POLB (0.53) | MCHR1CYP1A2CYP3A4CYP2C19SMN1; SMN2 | |
| SCHEMBL2987178 | 0.87 | ATF4 (0.58) | MCHR1SMN1; SMN2POLBLMNAATF4 | |
| SCHEMBL2982118 | 0.85 | MCHR1 (0.50) | MCHR1CYP1A2CYP3A4CYP2C19SMN1; SMN2 | |
| SCHEMBL2976726 | 0.83 | MCHR1 (0.54) | MCHR1CYP1A2CYP3A4CYP2C19SMN1; SMN2 | |
| SCHEMBL2981298 | 0.81 | ATF4 (0.56) | MCHR1SMN1; SMN2POLBLMNAATF4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7786328-B2 | Cyclohexyl-1,4-diamine compounds | GRUENENTHAL GMBH (DE) | 2010-08-31 | — | — | US | claimed |
| US-20070281954-A1 | Cyclohexyl-1,4-diamine compounds | GRUENENTHAL GMBH (DE) | 2007-12-06 | — | — | US | claimed |
| US-7786328-B2 | Cyclohexyl-1,4-diamine compounds | GRUENENTHAL GMBH (DE) | 2010-08-31 | — | — | US | disclosed |
| US-20070281954-A1 | Cyclohexyl-1,4-diamine compounds | GRUENENTHAL GMBH (DE) | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281954-A1 | Cyclohexyl-1,4-diamine compounds | DPYD, PKD1, AOC1 | MCHR1 1826/4885CYP1A2 100/4885CYP3A4 124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.